Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pittsburgh
University of Chicago
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Fulgent Pharma LLC.
University of Chicago
Gilead Sciences
Ohio State University Comprehensive Cancer Center
National Medical Research Radiological Centre of the Ministry of Health of Russia
University of Chicago
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Iovance Biotherapeutics, Inc.
University of Michigan Rogel Cancer Center
University of Chicago
Medical University of Vienna
University of Chicago
Thomas Jefferson University
Replimune Inc.
Latin American Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
West China Hospital
The First Affiliated Hospital with Nanjing Medical University
University of Chicago
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lyvgen Biopharma Holdings Limited
Centre Leon Berard
Rutgers, The State University of New Jersey
Sun Yat-sen University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Bristol-Myers Squibb